On 30th November 2020 questions were put in the House of Lords on vaccine distribution. The Bishop of Carlisle asked a question:
The Lord Bishop of Carlisle: My Lords, for obvious reasons we have focused largely on equal access to vaccines but, given the broader significance and implications of this Oral Question on affordable drugs and the fact that Global Cancer Week took place earlier this month, are any negotiations currently taking place on access to affordable cancer treatments, especially in developing countries? Continue reading “Bishop of Carlisle asks about access to affordable cancer treatments in developing countries”
On 7th June 2018 Lord Forsyth of Drumlean asked Her Majesty’s Government “what plans they have to ensure that clinicians in England are able to treat chronic lymphocytic leukaemia by prescribing Ibrutinib in accordance with NICE guidelines.” The Bishop of Carlisle, Rt Revd James Newcome, asked a follow-up question:
The Lord Bishop of Carlisle: My Lords, I am most grateful to the Minister for meeting some of the patients suffering from this terrible disease. Can he tell us whether anyone directly affected by blood cancer was consulted before the initial decision was made by NHS England to restrict access to Ibrutinib? Can he assure the House that NICE guidelines will not often be varied—and then only after consultation with patients? Continue reading “Bishop of Carlisle asks Government about access to treatment for leukaemia patients”
On 25th January 2018 Baroness Jowell hosted a debate in the House of Lords “To ask Her Majesty’s Government what action they are taking to evaluate innovative cancer treatments and make them available through the National Health Service, and to raise life expectancy for cancer patients”. The Bishop of Carlisle, Rt Revd James Newcome, spoke in the debate:
The Lord Bishop of Carlisle: My Lords, it is a great privilege to speak in this debate. I begin by observing that although, as we have heard, we currently have one of the worst cancer survival rates in Europe, the overall 10-year survival rate for all cancers in the UK has improved from 25% a few decades ago to 50% today. The laudable and ambitious goal of our cancer strategy is to make that 75% within the next decade, thereby not only catching up with but surpassing international, and especially European, averages. Cancer Research UK, among other agencies, is currently researching possible therapeutic interventions, many of them innovative, in a range of more than 200 different types of cancer, and that is something to celebrate. However, I suggest that three vital conditions need to be met if those aspirations are to be achieved. Continue reading “Bishop of Carlisle highlights need for cancer care improvements”
“I knew very little about mesothelioma until I became aware of its effects, not least through the early death in 2009 of the former Bishop of Peterborough, who some Members may recall” – Bishop of Newcastle
On 16th January 2014, the Bishop of Newcastle took part in Lord Alton’s debate on mesothelioma research funding.
The Lord Bishop of Newcastle: My Lords, I, too, am very grateful to the noble Lord, Lord Alton, for initiating this short debate. I speak to support him and to encourage the Government to enable the establishment of a mesothelioma research funding scheme as urgently as possible. Research into this form of cancer is very much the Cinderella of cancer research in the UK, and there is an urgent need for us to do more and to do better.
Continue reading “Bishop of Newcastle speaks of urgent need for mesothelioma research funding”